Epidemiological Study of Adamantinoma from US Surveillance, Epidemiology, and End Results Program: III Retrospective Analysis.
Journal
Journal of oncology
ISSN: 1687-8450
Titre abrégé: J Oncol
Pays: Egypt
ID NLM: 101496537
Informations de publication
Date de publication:
2020
2020
Historique:
received:
06
03
2020
revised:
04
05
2020
accepted:
21
05
2020
entrez:
3
7
2020
pubmed:
3
7
2020
medline:
3
7
2020
Statut:
epublish
Résumé
Adamantinomas are rare low-grade malignant bone tumors. This study aims to describe the demographic characteristics and survival rates of patients suffering from adamantinomas. The National Institute of Cancer Surveillance, Epidemiology, and Recent Results (SEER) database was used, and patients diagnosed with adamantinoma between 1973 and 2016 were screened. Patients were classified according to sex, age, race/ethnicity, and marital status, and also tumors were classified according to year of diagnosis, laterality, type of treatment, and follow-up. The mean age of patients was 30.8 ± 16.7 (range: 4-75). A total of 92 patients were identified; of these, 43 were females and 49 were males. The mean follow-up period was 138.1 ± 90.3 (range: 1-156) months. Mean survival duration was 287.8 ± 15.4 (95% CI: 257.7-317.9) months. Five- and ten-year survival rates were 98.8% and 91.5%, respectively. Besides, survival time was also observed to be independent of gender, age groups, race, marital status, tumor location, and year of diagnosis. Adamantinoma is a very rare bone tumor that affects the long bones in lower extremities and is more common in men. Five- and 10-year survival prognoses are reasonably satisfactory. Also, survival time is independent of variables such as gender, age, and tumor location.
Identifiants
pubmed: 32612653
doi: 10.1155/2020/2809647
pmc: PMC7315319
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2809647Informations de copyright
Copyright © 2020 Mahmut Nedim Aytekin et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
Clin Orthop Relat Res. 1986 Mar;(204):215-37
pubmed: 3514033
Diagn Pathol. 2008 Feb 15;3:8
pubmed: 18279517
J Surg Oncol. 2018 Dec;118(7):1150-1154
pubmed: 30332521
Acta Ortop Bras. 2018;26(4):252-254
pubmed: 30210255
Orthopedics. 2007 Mar;30(3):211-5; quiz 216-7
pubmed: 17375547
J Bone Joint Surg Am. 2000 Aug;82(8):1122-31
pubmed: 10954102
Hum Pathol. 2019 Sep;91:123-128
pubmed: 30496800
Cancer. 1989 Aug 1;64(3):730-7
pubmed: 2743266
J Med Case Rep. 2016 Jun 23;10(1):185
pubmed: 27337984
Orthopedics. 2014 Jun;37(6):362, 420-2
pubmed: 24972424
Bone Joint J. 2017 Mar;99-B(3):409-416
pubmed: 28249983
J Bone Joint Surg Am. 1994 Oct;76(10):1482-99
pubmed: 7929496
J Clin Epidemiol. 1997 Aug;50(8):939-45
pubmed: 9291879
J Am Acad Orthop Surg. 2010 Jun;18(6):358-66
pubmed: 20511441
Acta Orthop Traumatol Turc. 2019 May;53(3):189-194
pubmed: 30982757
Am J Surg Pathol. 2008 Mar;32(3):363-76
pubmed: 18300815
Acta Orthop Belg. 2007 Aug;73(4):425-31
pubmed: 17939469